Ipca LaboratoriesNSE:IPCALAB -0.18%86 Net Margin % is 12.52% as of Mar. 2026, which is 25% above its 10-year median of 10.04. GuruFocus rates NSE:IPCALAB with a GF Score™ of 86/100 and a GF Value™ of ₹1,594.77 (Fairly Valued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Ipca Laboratories ranks better than 69.87% on this metric.
The historical rank and industry rank for Ipca Laboratories's Net Margin % or its related term are showing as below:
NSE:IPCALAB'
s Net Margin % Range Over the Past 10 Years
Min: 6.29 Med: 10.04 Max: 21.25
Current: 11.83
NSE:IPCALAB's Net Margin % is ranked better than 69.87% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:IPCALAB: 11.83
Ipca Laboratories (NSE:IPCALAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ipca Laboratories Net Margin % Related Terms
Ipca Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipca Laboratories (NSE:IPCALAB) has a Net Margin % of 12.52% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Ipca Laboratories and its competitors. This is 25% above median its historical median of 10.04. Over the past decade, Ipca Laboratories' Net Margin % has ranged from 6.29 to 21.25. According to the industry distribution chart, Ipca Laboratories ranks #288 out of 956 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Ipca Laboratories' Net Margin % too high?
Ipca Laboratories' current Net Margin % of 12.52% is 25% above median its 10-year median of 10.04. Over the past 10 years, this metric has ranged from a low of 6.29 to a high of 21.25. The Drug Manufacturers industry median Net Margin % is 5.56. Ipca Laboratories' value of 12.52% is 125.2% above this industry median. Based on the distribution chart, Ipca Laboratories ranks #288 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ipca Laboratories has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #288 out of 956 companies for Net Margin %. This puts Ipca Laboratories in the upper half of its industry. The industry median Net Margin % is 5.56. Ipca Laboratories' value of 12.52% is 125.2% above this benchmark. Historically, Ipca Laboratories' own Net Margin % has ranged from 6.29 to 21.25 over the past decade. While the company's 10-year median is 10.04 vs. the industry median of 5.56, Ipca Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current Net Margin % of 12.52% is 125.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current Net Margin % is 12.52%, which is 25% above median its own 10-year median of 10.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,594.77, compared to a current price of ₹1,618.30 — trading 1.5% above its estimated fair value. The current Net Margin % is 12.52%, which is 25% above median its 10-year median of 10.04 and 125.2% above the Drug Manufacturers industry median of 5.56. Ipca Laboratories' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Net Margin % is 12.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,618.30 is trading 1.5% above its estimated GF Value™ of ₹1,594.77.
GuruFocus considers Ipca Laboratories to be Fairly Valued.
Key valuation signals for NSE:IPCALAB:
Net Margin %: 12.52% (25% above median its 10-year median of 10.04)
GF Value™: ₹1,594.77 vs. price of ₹1,618.30 (1.5% above fair value)
Industry Position: 125.2% above the Drug Manufacturers median (#288 of 956)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
86GF Score
Get the complete analysis for NSE:IPCALAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
